| Objective: The study evaluated the prognostic effect of levosimendan on the quality of life(QOL)of patients with acute onset of chronic heart failure,proposed new evaluation methods for the management and treatment of patients with acute onset of chronic heart failure,and provided useful data and new research directions for the prognosis of chronic heart failure treatment.Methods:From October 2019 to January 2021,61 patients with acute onset of chronic heart failure admitted to the Yijishan Hospital,the First Affiliated Hospital of Wanan Medical College,were randomly divided into two groups: the levosimendan group and the control group,of which 31 cases in levosimendan group and 30 cases in the control group.The control group received only conventional treatment for heart failure;the levosimendan group was given the same conventional heart failure treatment as the control group plus levosimendan.Monitor the patient’s vital signs before and after medication;observe the patient’s dyspnea,NYHA cardiac function classification,LVEF,BNP and QOL before medication and 14 days after treatment to evaluate the effect of levosimendan on the improvement of the patient’s quality of life.Results: 1.The general clinical data of the two groups of patients were not statistically significant(P >0.05),and they were comparable.2.The BNP of the two groups of patients decreased after treatment,and the BNP of the levosimendan group decreased more obviously,the difference was statistically significant(P <0.05).3.The LVEF of the two groups of patients increased after treatment,and the LVEF of the levosimendan group increased more significantly,the difference was statistically significant(P <0.05).4.The NHYA cardiac function classification of the two groups of patients improved after treatment,and the improvement of the NHYA cardiac function classification of the levosimendan group was more obvious,the difference was statistically significant(P<0.05).5.The degree of dyspnea of the two groups of patients improved after treatment,and the degree of dyspnea improvement in the levosimendan group was more obvious,the difference was statistically significant(P <0.05).6.The total MLFQ score of the two groups of patients decreased after treatment,and the total MLFQ score of the levosimendan group decreased more significantly,the difference was statistically significant(P <0.05).7.After treatment,HR,R,SBP,and DBP of the two groups of patients were all reduced.There was no significant difference between the levosimendan group and the control group,and there was no statistical significance(P >0.05).Conclusion: Levosimendan has obvious clinical effects,can be used to treat patients with acute onset of chronic heart failure in the clinical field,significantly lower BNP level,improve cardiac function,reduce clinical symptoms and improve the quality of life of patients. |
